Ionis Pharmaceuticals, Inc. with ticker code (IONS) now have 19 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between 88 and 26 calculating the mean target price we have $48.11. Given that the stocks previous close was at $40.71 this indicates there is a potential upside of 18.2%. There is a 50 day moving average of $36.03 and the 200 moving average now moves to $40.12. The market capitalization for the company is 6.05B. The stock price for Iron Mountain Incorporated is 42.28 USD
The potential market cap would be $7,149,646,751 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 4.05 and a -10.75% return on assets.
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on cardiovascular and neurology franchises. The Company’s products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over seven medicines in Phase III studies for nine indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)), Tofersen (SOD1) and Bepirovirsen. Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, Fesomersen, ION904 and IONIS-AGT-LRx.
